Crossject

ALCJFR0011716265

Filings

39 filings

All Inside information39 Voting rights and capital20 Annual financial report3 Earnings release3 AGM documents1 Share buyback1

22/05/2026
CROSSJECT announces the successful completion of an equity financing and warrant issuance for a total immediate gross amount of €15 million
Inside informationFR
25/03/2026
CROSSJECT appoints Lionel Seltz as Chief Financial Officer
Inside informationFR
25/03/2026
CROSSJECT publishes its 2025 financial results and confirms the strengthening of its operational, industrial and financial trajectory
Inside information
04/02/2026
Communiqué établissant le bilan semestriel du contrat de liquidité de la société CROSSJECT
Inside informationFrench
14/11/2025
CROSSJECT completes €5 million financing with Vatel Capital
Inside informationFR
30/10/2025
CROSSJECT annonce la mise à disposition du rapport financier semestriel au 30 juin 2025
Inside informationFrench
22/09/2025
CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam)
Inside informationFR
04/08/2025
CROSSJECT remains engaged during the summer break
Inside informationFR
08/07/2025
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE S1 2025
Inside informationFrench
01/07/2025
CROSSJECT annonce la cessation et la mise en œuvre d’un nouveau contrat de liquidité
Inside informationFrench
24/06/2025
CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause
Inside informationFR
11/06/2025
CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children
Inside informationFR
04/06/2025
Launch of a capital increase with preferential subscription rights for nearly 5 million euros
Inside informationFR
03/06/2025
Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00
Inside informationFR
27/05/2025
CROSSJECT implements new manufacturing module to scale-up the ZENEO® Factory ‘s versatility and capacity in anticipation of full product pipeline deployment
Inside informationFR
20/05/2025
CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval
Inside informationFR
15/05/2025
CROSSJECT’s ZENEO® needle-free autoinjector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors
Inside informationFR
07/05/2025
CROSSJECT provides updates on the EUA filing of ZEPIZURE®
Inside informationFR
27/03/2025
CROSSJECT reports financial results for 2024
Inside informationFR
25/03/2025
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program
Inside informationFR
18/03/2025
CROSSJECT achieves key ZEPIZURE® manufacturing batch stability milestones
Inside informationFR
12/02/2025
Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board
Inside informationFR

About

ISIN: FR0011716265
Ticker: ALCJ
LEI: 969500W1VTFNL2D85A65
Country of registration: FR
Last filing: 21/07/2026, 17:36

Sparse profile

The AMF publishes neither sector nor description. These fields are enriched from Wikidata where a match exists.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive